In addition, the CRP-positive group had significantly poorer cancer-specific survival compared with the CRP-negative group in stage III colorectal cancer patients with an inadequate number of examined lymph nodes (<12) or LNR <0.15 (log-rank test; lymph node number examined, p<0.05; LNR, p<0.01; Fig. 4A and C). This evidence concerns the gene CRP and colorectal cancer.